title: [Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
abstract: OBJECTIVE
  To investigate the treatment outcome, laryngeal preservation and side-effect in locally advanced hypopharyngeal carcinoma treated with combined Hilical tomotherapy (HT) or intensity-modulated radiotherapy (IMRT) and chemotherapy and/or EGFR inhibitor (Cetuximab or Nimotuzumab).
  
  
  METHODS
  A total of 68 patients (20 cases with T1-2N1-3M0 and 48 cases with T3-4N1-3M0) with locally advanced hypopharyngeal cancer were treated individualy with non-surgical combined modality treatments including induction chemotherapy followed by concurrent chemoradiotherapy, induction chemotherapy followed by concurrent radiotherapy and EGFR inhibitor, concurrent chemoradiotherapy and EGFR inhibitor, and concurrent radiotherapy and EGFR inhibitor. HT was used in 40 patients and IMRT in 28 patients. Side-effects were evaluated with the established Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria.
  
  
  RESULTS
  The average follow-up time was 25.7 months (range 3-69 months). All patients completed the planned radiotherapy without treatment breaks, and 66 (97.0%) of 68 patients completed the planned chemotherapy. The 2-year and 3-year overall survival rates were 78.8% and 64.7% respectively, with an organ preservation rate of 84.2%. The most common side-effect greater than or equal to grade 3 was oropharyngeal mucositis. No patient dependent on a percutaneous gastrostomy and tracheostomy tube.
  
  
  CONCLUSIONS
  Hypopharyngeal carcinoma can be treated with non-surgical combined modality treatment including HT or IMRT, with a high laryngeal organ preservation rate and minimal toxicities.
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, General Hospital of People Liberation Army, Beijing 100853, China. Email: xinxinzhang66@hotmail.com.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Zhang
authors.forename: Jialing
authors.initials: J
authors.lastname: Wang
authors.forename: Wenming
authors.initials: W
authors.lastname: Wu
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.forename: Mingbo
authors.initials: M
authors.lastname: Liu
authors.forename: Feifan
authors.initials: F
authors.lastname: Zhao
authors.forename: Deliang
authors.initials: D
authors.lastname: Huang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D000068818:Cetuximab; D059248:Chemoradiotherapy; D002945:Cisplatin; D003131:Combined Modality Therapy / Q000379:methods*; D005472:Fluorouracil; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000628:therapy*; D007830:Larynx; D007831:Larynx, Artificial; D009926:Organ Preservation; D050397:Radiotherapy, Intensity-Modulated; D000077195:Squamous Cell Carcinoma of Head and Neck; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C501466:nimotuzumab; D000068818:Cetuximab; D002945:Cisplatin; D005472:Fluorouracil